Proportion of Osteoporotic Women Remaining at Risk for Fracture Despite Adherence to Oral Bisphosphonates by Imel, Erik A. et al.
Proportion of Osteoporotic Women Remaining at Risk for Fracture Despite 
Adherence to Oral Bisphosphonates 
Erik A. Imel1,2, George Eckert3, Ankita Modi4, Zhuokai Li3, Joel Martin2, Anne de 
Papp4, Katie Allen2, C. Conrad Johnston1, Siu L. Hui2,3, Ziyue Liu3 
1Indiana University School of Medicine, 2Regenstrief Institute, 
3Indiana University School of Public Health 
4Merck, Sharp and Dohme, Inc., 
Corresponding author:  
Erik A. Imel 
eimel@iu.edu 
Division of Endocrinology and Metabolism 
Department of Internal Medicine 
Indiana University School of Medicine 
1120 W. Michigan Street 
Gatch Clinical Building 459 
Indianapolis, Indiana 46202-5111 
Telephone: 317-274-1339 
Fax: 317-278-0658 
Acknowledgements: 
Funding Source: This research was funded by a grant under the Merck- Regenstrief 
Program in Personalized Health Care Research and Innovation, a collaboration 
between Merck, Sharp & Dohme and the Regenstrief Institute.  
Conflict of Interest Disclosures: Erik A. Imel has received research funding from Merck, 
Sharpe & Dohme. Ankita Modi and Anne de Papp are employed by Merck, Sharpe & 
Dohme. All other investigators declare that they have no conflict of interest. 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Imel, E. A., Eckert, G., Modi, A., Li, Z., Martin, J., de Papp, A., … Liu, Z. (2016). Proportion of osteoporotic women remaining at 
risk for fracture despite adherence to oral bisphosphonates. Bone, 83, 267–275. http://doi.org/10.1016/j.bone.2015.11.021
Abstract: 
Background:  Adherence to oral bisphosphonates is often low, but even adherent 
patients may remain at elevated fracture risk. The goal of this study was to estimate the 
proportion of bisphosphonate-adherent women remaining at high risk of fracture. 
 
Methods: A retrospective cohort of women aged 50 years and older, adherent to oral 
bisphosphonates for at least two years was identified, and data were extracted from a 
multi-system health information exchange. Adherence was defined as having a 
dispensed medication possession ratio ≥0.8. The primary outcome was clinical 
occurrence of: low trauma fracture (months 7-36), persistent T-score ≤-2.5 (months 13-
36), decrease in bone mineral density (BMD) at any skeletal site ≥5%, or the composite 
of any one of these outcomes. 
 
Results: Of 7435 adherent women, 3110 had either pre- or post-adherent DXA data. In 
the full cohort, 7% had an incident osteoporotic fracture. In 601 women having both pre- 
and post-adherent DXA to evaluate BMD change, 6% had fractures, 22% had a post-
treatment T-score ≤-2.5, and 16% had BMD decrease by ≥5%. The composite 
outcomes occurred in 35%. Incident fracture was predicted by age, previous fracture, 
and a variety of co-morbidities, but not by race, glucocorticoid treatment or type of 
bisphosphonate. 
 
Conclusion: Despite bisphosphonate adherence, 7% had incident osteoporotic fractures 
and 35% had either fracture, decreases in BMD, or persistent osteoporotic BMD, 
representing a substantial proportion of treated patients in clinical practices remaining at 
risk for future fractures.  Further studies are required to determine the best achievable 
goals for osteoporosis therapy, and which patients would benefit from alternate 
therapies. 
 
 
 
  
Highlights: 
 In women adherent to oral bisphosphonates 7% had incident osteoporotic fracture. 
 In those with DXA pre and post adherence, 22% had persistent osteoporotic T-
scores. 
 In those with DXA pre and post adherence, 16% had BMD declines ≥5% at any site.  
 A third of patients had one or more of these outcomes despite adherence to oral 
bisphosphonates.   
 
  
1. Background:   
 
Osteoporosis is a condition of low bone density leading to fracture. Each year over 1.3 
million fractures occur in the United States, the majority of which are due to age-related 
osteoporosis [1].  In 2010,  54 million adults age 50 and older in the United States were 
estimated to have osteoporosis or osteopenia as defined by BMD measurement  [2]. 
Though the age-specific rates of hip fractures have been reported to be decreasing in 
some, albeit not all, countries [3, 4], osteoporosis remains a major public health problem 
that will continue to increase in prevalence as the population ages. 
Despite the availability of highly efficacious treatments for osteoporosis such as oral 
bisphosphonates, low treatment initiation rates [5] and low adherence among patients in 
clinical settings [6] limits the benefits.  In clinical trials, osteoporosis agents decrease hip 
fractures by up to 50%, vertebral fractures by 30-70% (depending on whether detected 
based on clinical symptoms or morphometry), and nonvertebral fractures by up to 30% 
[7, 8]. When patients are adherent and persistent in their treatments, the reduction in 
fracture rates has been reported to be similar between clinical trials and observational 
cohorts [9]. However, no osteoporosis treatment eliminates fractures and some patients 
that are adherent and persistent in their osteoporosis treatments may remain at 
elevated risk for future fractures. 
A group of clinician/researchers have suggested a goal-directed strategy to initiate or 
change osteoporosis treatments based on targets to achieve a certain BMD value or 
level of fracture risk [10].  Concerns regarding difficulties in setting achievable goals 
have been raised [11],  and these difficulties were later demonstrated empirically by 
showing that the FRAX Score was not responsive enough to treatment to be reliably 
used as target [12].  
A working group for the International Osteoporosis Foundation (IOF) proposed a set of 
criteria for defining inadequate clinical treatment response (which may or may not be 
due to low adherence) that included the occurrence during osteoporosis treatment, of 
two or more incident fragility fractures, a significant decrease in bone mineral density 
(BMD), (i.e. beyond the LSC of the measurement method), or change in bone turnover 
markers in the opposite direction of that induced by the treatment agent’s mechanism 
[8]. It was suggested that although these patients may have had some benefit from their 
osteoporosis drug regimen, that the occurrence of any of these criteria may indicate a 
need to consider altering treatment in such patients to optimize risk reduction. The 
occurrence of one or more fractures is a risk factor for additional future fractures in both 
untreated patients [13], and in those treated with bisphosphonates [14]. Furthermore 
persistence of osteoporotic T-scores or further decrease in BMD after treatment 
indicates a higher risk of subsequent fracture compared to those with higher post 
treatment T-scores, and potential to benefit from additional treatment [15]. Thus the 
outcomes of fracture, or the surrogate outcomes of decline in BMD or persistent low 
BMD, are often used by practitioners to guide decisions regarding continuing or 
switching therapies, because the occurrence of each of these is associated with an 
elevated risk of fracture relative to other treated patients [16, 17]. 
The various criteria proposed for inadequate response can be adapted and applied to 
electronic medical records to identify patients remaining at high risk for fractures despite 
treatment. Based on readily available data in the clinical records, patients on treatment 
can be assessed for whether 1) they incur one or more fractures while adherent to 
treatment, 2) their BMD remains low, or 3) their BMD decreases significantly while 
adherent to treatment. The primary objective of this analysis was to estimate the 
proportion of osteoporotic women in a large clinical medical records system who, 
despite having been adherent to oral bisphosphonate therapy, remain at high risk of 
fracture, as indicated by the occurrence of one of these three outcomes.  We also 
identified clinical and demographic factors associated with remaining at high risk. 
2. Methods 
2.1 Overview and Study Design   
This is a retrospective cohort study of women aged 50 years and older, who have 
been adherent to oral bisphosphonates for at least two years. The cohort was 
identified and all study data were extracted from a health information exchange as 
described below.   
2.2 Data Source and Definitions 
The study cohort and data were extracted from the Indiana Network for Patient Care 
(INPC), a leading operational regional Health Information Exchange formed in 1994 by 
the Regenstrief Institute and the five major hospital systems in Indianapolis, later joined 
by dozens more institutions around the state. Data types available from different 
institutions include diagnoses (ICD-9 codes), procedures (CPT codes), pharmacy 
transactions, orders, imaging studies, and laboratory results, though data completeness 
varies across INPC institutions.  The study was approved by the Institutional Review 
Board of Indiana University. The study subjects were restricted to only those patients 
who had been adherent to at least one oral bisphosphonate for two years (see 
inclusion criteria below).  Data from all hospitalizations including emergency room 
visits within the participating health systems are included in this dataset.  In 2004 a 
program was initiated to send data from all emergency room visits in the state of 
Indiana to the INPC (including emergency room visits at hospitals that do not send 
other data), which would increase the capture of fractures. 
Dual-energy x-ray absorptiometry (DXA) measurements of bone mineral density 
(BMD) and their associated T-scores at the spine, femoral neck, and total hip were 
available in a subset of patients whose health systems submitted such data to the 
INPC.  The BMD data included a combination of direct uploads from four DXA 
machines (11% of the total BMD data in this analysis) and data parsed from text 
reports (89%). The data directly uploaded from DXA machines (which included three 
machines used for medical research) incorporated both T-score and the BMD 
values in g/cm2. For quality control of data obtained from text reports, the T-scores 
were plotted against the BMD values in g/cm2, and compared to the equations for 
BMD measurement locations (total hip, femur neck, lumbar spine) according to 
different DXA machine manufacturers. Deviations from these equations triggered 
manual reviews of the reports and obvious typographical errors were corrected.  
When the deviation could not be reconciled, the data were excluded.  For the 
analysis of the complete-outcomes subcohort (having both pre and post index DXA), 
only reports listing BMD measures in g/cm2 listed were included.   
Clinical osteoporotic fractures were identified by ICD-9 codes (Supplemental Table 
1). Fractures at the following sites not typically associated with osteoporosis were 
excluded: skull, craniofacial, phalangeal, carpal, metacarpal, tarsal, and metatarsal  
fractures.  Fractures were excluded as outcome events if records indicated 
concurrent fractures at 5 or more different skeletal sites (coded within a 30 day 
window), suggesting a high trauma event. The arbitrary cutoff of 5 fractures was 
based on a limited chart review of occurrence of co-incident fracture codes and an 
estimate of the likely range in number of possible fractures occurring with low 
trauma vs high trauma events. However, in analysis no subject in our study had 
more than 3 concurrent fractures. Comorbidities were extracted from ICD-9 codes 
and medications were extracted from dispensing records. 
2.3 Inclusion/exclusion Criteria  
The study time period spanned 2000-2012, when bisphosphonates were widely 
used.  Only women aged 50 years and over were included if they satisfied the 
criterion for adherence to at least one oral bisphosphonate over at least two years, 
regardless of whether they had any indications for treatment.  Adherence was 
defined as “proportion of days covered” (PDC) [18] of at least 0.8 over 2 years, with 
no gap greater than 30 days between covered days.  Only the first documentable 
continuous adherent period of at least 2 years for each subject was included in the 
study. The date at the beginning of the adherent period was considered the index 
date, and the woman’s age at the index date was her index age.  Excluded were 
patients with osteogenesis imperfecta, hypercalcemia or Paget’s disease ICD9 
codes. Patients that had a record of intravenous bisphosphonate treatments or 
denosumab from 2 years prior to the index date through the adherent period were 
excluded.  Other pre-index osteoporosis treatments, including oral bisphosphonates 
that did not meet the criteria for adherence prior to the index date, and calcitonin or 
teriparatide, were treated as covariates in modeling outcomes. Concurrent 
medications during the adherent period (which sometimes included calcitonin, 
estrogens or selective estrogen receptor modifiers, as well as medications for co-
morbidities) were also treated as covariates.  However, the use of teriparatide, 
intravenous bisphosphonates and denosumab were exclusionary if occurring during 
the adherent period.  
2.4 Study outcomes  
2.4.1 Outcome definitions 
Outcomes for patients who had been adherent to oral bisphosphonates for at least 2 
years (and may or may not be adherent in the third year) were measured through 
month 36 from the index date because the effects of bisphosphonates last beyond 
the treatment period [19].  Patients were considered to remain at high risk of 
fracture if they satisfied at least one of the following three criteria: 
1) Low post-treatment T-score - defined as a T-score of ≤-2.5 at any of the 
following skeletal sites (spine, femur neck or total hip) during months 13-36 
from the index date.  
2) Significant decline in BMD - defined as a decrease of ≥5% (at any of the 
measured sites: spine, femur neck or total hip) these measured skeletal site 
from the pre-treatment BMD (latest value within 2 years prior to the index 
date) to any post-treatment value during months 13-36 from the index date. 
3) Any clinically coded non-traumatic osteoporotic fracture (as defined above; 
codes listed in supplemental Table 1) occurring in months 7-36 from the 
index date. 
Osteoporotic fractures were counted as events beginning after completing month 6 
because fracture rates in treated and untreated patients begin to diverge between 
treatment and placebo arms in the first 6-12 months in randomized trials of oral 
bisphosphonates [20, 21].  In contrast, to allow adequate time for BMD response to 
oral bisphosphonates, post-index BMD measurements were counted only from the 
beginning of month 13 onwards (i.e. from 13-36 months).  While the fracture 
outcome could be ascertained on the entire cohort, the outcome of low post-
treatment T-score could be ascertained only on the subset of subjects with BMD 
measurements in months 13-36 from the index date.  The choice of -2.5 as a cutoff 
for the post-treatment T-score is based on the patient still meeting the definition of 
osteoporosis.  The IOF recommends a decrease of 4-5% in BMD be generally 
considered a significant decline, depending on the precision of the individual 
machine [8].  Since the INPC data were received from multiple institutions with 
variable levels of quality control in their DXA measurements and the precision level 
for most contributing machines is not provided to INPC, the higher 5% value was 
chosen to indicate a significant decline. A composite outcome of “remaining at risk 
of fracture” was defined as a positive outcome in any one of the 3 individual 
outcomes.  This could be ascertained only in the complete-outcomes subcohort. 
2.4.2 The complete-outcomes subcohort 
 Within this subset, the outcome of a significant drop in BMD could be ascertained 
only in those subjects who also had at least one BMD measurement at the 
corresponding skeletal site(s) during the two years prior to the index date. This 
smallest subset of 601 subjects, having both pre- and post-treatment BMD during 
the defined periods, comprised the “complete-outcomes subcohort”.   
2.5 Covariates 
Patient demographics included age and race. Clinical characteristics included 
fractures and osteoporosis drug treatments prior to the index date, type of 
bisphosphonate and other co-medications used during the adherent period, and 
chronic comorbidities.  Comorbidities were captured by ICD-9 codes. The Charlson 
Comorbidity Index was calculated, using a modified version excluding age as a 
factor [22]. The Charlson Comorbidity Index is generated from ICD9 codes to 
categorize burden of comorbidities. A higher score on the Charlson Comorbidity 
index indicates greater number or degree of comorbidities and is a predictor for 
mortality or for complications in a variety of disease states [22, 23]. In addition 
codes for other major disease groups and selected conditions that may affect bone 
metabolism or risk of falls were also collected.  
2.6 Statistical Analyses 
Descriptive statistics were calculated for the entire cohort, and in the complete-
outcomes subcohort (having both pre and post index DXA). Subject characteristics 
and fracture outcomes of the subcohort were compared to subjects not in the 
subcohort to identify how the subcohort might differ systematically from the 
remainder of the overall cohort. A p-value of <0.05 was considered statistically 
significant. 
Logistic regression modeling was used to identify factors that predict outcomes. 
Predictors included demographic and clinical characteristics of the subjects.  
Preliminary analyses used only one predictor in each model to examine apparent 
associations.  Then stepwise model selection was used to fit multivariable models. 
Predictors in the stepwise multivariable model were not pre-selected; however, pre-
index T-score was excluded from the analysis because of strong relationship with 
post-treatment T-scores. For inclusion of a variable, p-values of 0.05 or less were 
required for inclusion versus elimination from the model at each step. A model was 
fitted to predict fractures since this outcome was available on the entire cohort, and 
the results could be compared to other studies.  The model for predicting the 
composite outcome was then fitted to the complete-outcomes subcohort.  Sensitivity 
analyses were also performed by using a 3% drop in BMD rather than 5% for the 
definition of a significant drop.  Comparison between BMD change category and 
fracture occurrence was conducted using Mantel-Haenszel chi-square test (using 
the ordinal BMD change categories). 
3. Results 
The study cohort was selected from an initial set of 8,339 women who had been 
adherent to oral bisphosphonate treatments for at least 2 years.  Figure 1 shows the 
application of the various exclusion criteria resulting in the final analysis cohort of 
7435 women. Only 3110 in this cohort had any DXA data in the two-year pre-index 
period and/or months 13-36 post-index. In a small subset of reports, only T-scores 
were reported without the absolute BMD values (0.07% of reports at the total hip, 
6.9% at the femur neck, 0.1% at the spine). Of the 620 subjects who had DXA 
measurements in both the requisite pre- and post-treatment periods, only 601 had 
BMD values at the same skeletal site (and measured in g/cm2) in both periods so 
that percent change in BMD could be calculated, and these subjects comprised the 
“complete-outcomes subcohort.”  
Table 1 shows the characteristics of subjects in the overall cohort, and in the complete-
outcomes subcohort (having at least one pair of DXA measurements in the eligible pre- 
and post-treatment periods at the same skeletal site).  Patients in the complete-
outcomes subcohort were younger (p<0.01), and were more likely to be white 
(p<0.0001) compared to the rest of the cohort.  Since the vast majority of patients in 
INPC are white (most likely including those with missing race), subsequent analyses 
used black and non-black categories, with proportions similar between the complete-
outcomes subcohort and the entire cohort.  Subjects in the complete-outcomes 
subcohort had a longer adherent period (p<0.001), and were less likely to have diabetes 
(p<0.05). During the pre-index period, subjects in the complete outcomes subcohort 
were also more likely to have received any previous osteoporosis treatment (p<0.01), 
any previous bisphosphonate (p<0.05), or alendronate (p<0.001), than those in the full 
cohort. 
Table 2 shows the different oral bisphosphonates dispensed during the adherent 
periods.  In each cohort, a small subset received more than one oral bisphosphonate 
sequentially during the study period. Subjects in the complete-outcomes subcohort were 
more likely to have taken alendronate (p<0.01) and less likely to have taken risedronate 
during the adherent period (p<0.01).  Other co-medications taken in the same period 
are also presented; only estrogens were taken by a smaller proportion of subjects in the 
complete-outcomes subcohort (p<0.05). 
Table 3 summarizes the study outcomes in the post-index period.  Of the entire 
cohort of 7435 women, 499 (7%) had at least one coded clinical fracture event and 
174 (2%) had 2 or more distinct fracture events between 7 & 36 months post-index. 
In our cohort most fracture events involved single fractures.  Between the index 
date and 3 years after index there were 506 individual fracture events in patients 
with only 1 fracture at a time, 76 with 2 co-incident fractures, 13 with 3 co-incident 
fractures, and none with 4 or more co-incident fractures. However, only fractures 
occurring from months 7-36 were counted as outcomes in the analysis. From 7-12 
months after index, 122 fracture events occurred; from 13-24 months, 288 fracture 
events occurred; and from 25-36 months, 367 fracture events occurred. The 
osteoporotic fracture rate was similar in the complete-outcomes subcohort (6%) to 
the entire cohort (7%). 
A low post-treatment T-score ≤-2.5 occurred in 20% of the full cohort having 
available DXA data, and in 22% of the complete-outcomes subcohort (having pre- 
and post-treatment DXA). Decline in BMD could only be assessed in the complete-
outcomes subcohort.  Pre-index, 152 women started with T-scores ≤-2.5, of which 
55 (36%) had post adherent T-scores >-2.5. Of the remaining 449 women starting 
with pre-index T-scores >-2.5, 34 (8%) ended with post-adherent T-scores ≤-2.5. 
Out of the 131 women who ended with T-scores ≤-2.5, 97 (74%) of them had started 
with pre-index T-scores ≤-2.5. The percent of subjects having BMD increases or 
decreases ≥5%, or with BMD remaining within <±5% are listed in Table 3. Not every 
patient had data available for all 3 sites. In this subcohort, more patients had 
increases of BMD at the spine (37%), while more patients had decreased BMD at 
the femur neck (16%). When assessed for the worst BMD change at any measured 
site, 16% of adherent women had a decline in BMD ≥5% during treatment at one or 
more sites.  
The composite outcome of having at least one of the three outcomes is only 
assessable in the complete-outcomes subcohort having both pre- and post-adherent 
DXA. In this subgroup we identified 207/601 (35%) with positive composite 
outcomes: of these 207 women, 64% had a T-score ≤-2.5; 47% had a significant 
decline in BMD ≥5%; and 18% had a clinical fracture.  
Table 4 shows the univariate estimates of association between the risk of a fracture 
outcome and each covariate, except for the use of thiazides, proton pump inhibitors, 
SSRIs/SNRIs, anticonvulsants, statin, antidiabetics, anticoagulants, and 
cyclosporins, which were not associated with any outcome in any analyses.  The 
significant predictors of fracture include the well-known risk factors of age, previous 
fracture and low T-scores, as well as a number of chronic diseases. Black (versus 
non-black) race was not a predictor of fracture. The types of oral bisphosphonates 
were not associated with fracture outcomes, but the use of calcitonin before or 
concurrently with bisphosphonate treatment had an association with higher fracture 
risk, possibly due to providers treating those deemed at higher risk with dual 
therapy. Similarly those with previous treatment with teriparatide were also at higher 
risk of fracture during subsequent bisphosphonate adherence, likely identifying 
potent anabolic therapy being used in those at highest baseline risk. Higher 
Charlson Comorbidity Index and multiple individual comorbid conditions including 
AIDS, malignancy, chronic pulmonary diseases, chronic joint conditions, neurologic, 
cardiovascular, gastrointestinal and renal conditions and diabetes were all 
associated with increased risk of fracture despite bisphosphonates.  Concomitant 
glucocorticoids were not predictive of fracture while adherent to bisphosphonates. 
Other co-medications during the adherent period did not predict fracture outcomes, 
though there was a nonsignificant trend for increased risk of fracture with use of 
tamoxifen. 
When the univariate analyses in Table 4 were applied to the complete-outcomes 
analysis subcohort for associations with the composite outcome, the associations 
with individual predictors remained similar for the known osteoporosis factors of 
age, previous fracture and low T-scores, but weakened for most chronic conditions 
(as measured by odds ratio). However the associations with pre- and post-index use 
of calcitonin remained and had more extreme odds ratios, even though the p-values 
were larger due to the smaller sample size. 
After all potential predictors (regardless of significance in univariate analyses) were 
entered stepwise into a multiple logistic model, age and previous fracture remained 
predictive of fractures in the study period, as did the modified Charlson Comorbidity 
Index and several individual chronic conditions.  Pre-index (nonadherent) use of 
alendronate was associated with a lower fracture risk during subsequent oral 
bisphosphonate adherence, while pre-index use of calcitonin was associated with a 
higher subsequent fracture risk (see Table 5).  Black race and pre-index T-score 
category (>-1, -1 to -2.5, <-2.5) did not predict fractures in multiple logistic 
regression. The OR for the composite outcome was increased by age, race (non-
black), hyperparathyroidism, and use of estrogens.    
As a secondary analysis, predictors of decline in BMD ≥5% were analyzed in the 
complete-outcomes subcohort, having pre and post adherent DXA. In univariate 
analysis of association the type of oral bisphosphonates was not a significant 
predictor of BMD decline. Each oral bisphosphonate was individually compared to 
the other two. BMD decreased ≥5% in 21% of patients treated with risedronate 
versus 15% of patients with other oral bisphosphonates (p=0.08); in 17% of patients 
treated with ibandronate versus 16% of patients with other oral bisphosphonates 
(p=0.93); and in 16% of patients treated with alendronate versus 18% of patients 
with other oral bisphosphonates (p=0.60). Variables increasing odds ratio for BMD 
decrease in stepwise multivariable analysis included age (p=0.0377, odds ratio 1.03 
(1.00, 1.05)), chronic pulmonary diseases (p=0.0270, odds ratio 1.74 (1.07, 2.85)), 
and estrogen use (p=0.0183, odds ratio 2.39 (1.16, 4.93)).  The type of 
bisphosphonate was not significant in stepwise multivariable models.  
In the complete-outcomes subcohort, the occurrence of one or more fractures from 
month 7-36 was not related to different levels of change in BMD (Mantel-Haenszel 
chi square test p=0.56). Of 98 patients in whom BMD decreased by ≥ 5%, 8 (8%) 
sustained fracture. Of 434 patients without change in BMD (BMD within ± <5%), 22 
(5%) of patients sustained fracture. In 69 patients BMD increased by ≥ 5%, and 8 
(12%) had fracture.  Similarly when BMD was treated as a continuous variable, 
there was no relationship with clinical fracture incidence (p=0.73). 
When limiting to 2 or more clinical fractures as an outcome, for the multivariable 
analysis the significant variables and the odds ratios were similar and fairly stable 
(Supplemental Table 2) compared to those using 1 or more fractures as an outcome 
(Table 3). This was true for fractures as the endpoint, and also for the composite 
outcome. However in this analysis, risedronate use (compared to other 
bisphosphonates) was associated with the composite outcome including 2 or more 
fractures, while it was not associated with a composite outcome including 1 or more 
fractures.   
4. Discussion 
In a population of patients from a health information exchange network, we 
estimated that patients who have been adherent to oral bisphosphonates for at least 
two years have an absolute clinical fracture risk of 7% (including both vertebral and 
non-vertebral fractures) during months 13-36 from the beginning of the adherent 
period.  These patients can be interpreted as remaining at high risk of fractures in 
part because past fractures predict future fractures.  In the subset of patients with 
sufficient bone density measurements to determine declines in bone density, we 
estimated that 35% remained at risk for osteoporotic fractures based on the 
occurrence of either: one or more fractures while adherent to bisphosphonates, a T-
score remaining in the osteoporotic range, or a significant decrease in BMD during 
two to three years of treatment.   
The International Osteoporosis Foundation Inadequate Responders Working Group 
[7] proposed pragmatic criteria suggesting inadequate response to osteoporosis 
treatment including occurrence of two or more fractures, or a decrease in BMD, or 
change in bone turnover markers inconsistent with the specific drug mechanism of 
action. Unfortunately, this clinical patient care database did not have bone turnover 
marker data for analysis in this adherent population. Some authors have suggested 
that a persistent osteoporotic T-score indicates patients at higher fracture risk, who 
might not be candidates for drug holidays [23].  Similarly some authors have 
proposed considering a BMD target (such as achieving a non-osteoporotic T-score) 
as a hypothetical goal of treatment [9], based on the finding that persistent BMD T-
scores less than -2.5 after treatment with alendronate indicated a higher risk of 
subsequent fracture in the FLEX trial [14]. The occurrence of any fracture is still a 
risk factor for future fractures in both untreated patients [12], and in bisphosphonate 
treated subjects [13]. In a FIT trial analysis, out of 1841 patients receiving 
alendronate 248 (13.5%) sustained a first symptomatic fracture. Out of that  
subgroup of 248 subjects with first fracture, 51 (or 20.6%) sustained a second 
symptomatic fracture on treatment. Thus, even on oral bisphosphonates, the 
occurrence of one fracture indicated higher risk of subsequent fracture (compared to 
risk of first fracture on treatment) [13]. Of note the risk of a second fracture while on 
alendronate in that trial was still less than the risk of second fracture in the placebo 
group. We sought to apply a combination of these proposed factors as indicating a 
potential increased fracture risk, by collectively assessing the occurrence of one or 
more fractures while adherent to bisphosphonates, a T-score remaining in the 
osteoporotic range, or a significant decrease in BMD at either the hip or the spine.   
The advantage of using health information exchange data is that it  reflects real-life 
practice and patient behavior from a wide range of types of practices and patient 
backgrounds. Strengths of this study include its assessment of the effectiveness of 
actual treatment practices in our population, and the inclusion of clinical DXA and 
documented coded fractures as outcomes.  However, there are limitations to using an 
administrative database to make inferences regarding the outcomes of clinical treatment 
modalities, and for determining which patients might require a change in therapy.   
One limitation regarding outcome measurement includes that actual clinical practice 
may not result in the timing of sequential bone density measurements being on 
either side of clear time periods of treatment adherence and at appropriate intervals 
to assess the BMD outcomes in all subjects. The bone density related outcomes 
were limited to those patients whose BMD studies were performed at appropriate 
time intervals in relation to the actual adherent period. Thus not all subjects had 
both pre and post adherent period DXA scans.  In clinical practice significant time 
intervals may occur between a diagnostic DXA scan, and the initiation of therapy, 
while the actual adherence periods to therapy may be variable within an individual 
patient. In addition clinical DXA scans may not be timed around an adherent period, 
but may be planned based on payor coverage, or other factors. Likewise in clinical 
practice some patients may have had initial or post-treatment DXA scans at facilities 
that were outside the INPC networks. Another limitation of our study is that clinical 
DXA measurements are likely to have lower precision than DXA performed on 
research units, and for this study the least significant change information was not 
accessible.  While we expect the T-score to be reasonably reliably measured in 
clinical practice, the measure of BMD change likely does not attain the precision 
expected from research trials.  It is possible that the least significant change is 
higher than 5% in clinical practice facilities where some technicians may not be 
rigorously trained.  However, it is important that we used the same information that 
the patient’s treating clinician would have received, and which would impact clinical 
decision making. Thus the results seen in this study likely represent the situation 
faced by many treating clinicians.  
Our study could only detect fractures that were clinically recognized and coded.  
Thus asymptomatic morphometric vertebral fractures are less likely to be included.  
Furthermore, some fractures will be missed if not evaluated or treated within the 
participating health systems. If such fractures occurred, our results would be an 
underestimate of the true fracture incidence in patients adhering to oral 
bisphosphonates. However, because of the robust statewide emergency room data 
and extensive hospitalization data, most clinical fractures occurring in the state are 
likely to be captured.  
This study result may underestimate the risk of these outcomes in osteoporotic 
patients treated with bisphosphonates, as this was a subset of adherent patients [6]. 
Because patients may not become immediately adherent at the start of an initial 
prescription, patients were allowed to have oral bisphosphonates dispensed prior to 
the start of the recorded adherent period.  Of note, this ‘sub-adherent’ treatment 
would still likely have some effect on bone turnover, thus inclusion of these subjects 
would tend to decrease the estimate of subjects having one or more of the outcome 
events.  Interestingly, those patients with ‘sub-adherent’ alendronate treatment prior 
to the adherent period did have lower fracture risk in multivariable analysis [OR 0.69 
(95% CI 0.54, 0.89)], likely due to the cumulative effects of treatment with 
bisphosphonates even though initially used in a sub-adherent manner.  
Compliance was assessed based on drug dispensing days covered, with the 
assumption that the medication once obtained was actually taken properly and 
reliably by the patient. However, neither appropriate provider instructions, nor 
correct administration by the patient (i.e. without food, etc.), can be assured in this 
study.  Additionally, a comparator group of non-treated or non-adherent patients was 
not analyzed, in part because while dispensing of medications could be confirmed, lack 
of treatment is more difficult to ascertain with certainty, as patients may receive 
prescriptions at non-participating pharmacies. Of note, previous studies have suggested 
that bisphosphonate treatment as assessed in clinical databases indicates similar 
relative fracture risk reduction as in trials, which correlated to adherence rates [24, 25]. 
However prospective trials following adherent oral bisphosphonate treated subjects in 
clinical practices would better define the occurrences of these outcomes. 
Our data cannot specifically guide treatment choices in subjects having one of these 
events, as we could not evaluate the effect of treatment changes in the subgroup 
having incident fractures, decreasing BMD or persistent osteoporotic T-scores. 
There are some published data from clinical trials of switching subjects from oral 
bisphosphonate to other agents (nicely reviewed by Eiken and Vestergaard [26]). 
Studies in prior bisphosphonate users have indicated BMD increases at the spine or 
total hip after switching to denosumab or teriparatide, although a transient decrease 
in areal BMD at the total hip occurred during the first 6 months of teriparatide. 
Switching from alendronate to zoledronate or raloxifene did not increase BMD 
further. However, the trials of treatment switching generally did not limit enrollment 
to subjects having fractures or one of the BMD outcomes listed in our trial, but 
rather included subjects on an oral bisphosphonate regardless of previous treatment 
response. Thus it is not certain whether patients with incident fractures, decreasing 
BMD or persistent low T-scores while adherent to oral bisphosphonates would 
actually benefit from a switch to other osteoporosis agents. Prospective trials with 
these specific enrollment criteria would be needed to address this issue. 
Since our study only included subjects during a period of time with adherence to 
oral bisphosphonates, the findings are not generalizable to subjects receiving 
intravenous bisphosphonates. Patients sustaining fractures on treatment may have 
been switched to intravenous bisphosphonates, in which case their potential eligible 
time in the study period would have ended, and they would not have been included 
in our study if the oral bisphosphonate treatment was for less than 2 years. Thus 
higher risk subjects might have been excluded from the study, which would likely 
lead to an underestimate of the incidence of fracture or the BMD outcomes. 
Furthermore patients with contraindication to oral bisphosphonate would be 
excluded from this study regardless of whether they had higher or lower risk of 
fracture compared to the studied population. Higher risk patients on oral 
bisphosphonates who may have refused other therapies also could have biased the 
results in favor of higher incidence of outcomes. 
This study represents a cross-section of individual risk.  Patients at higher baseline 
risk of fracture benefit the most from therapy targeted at reducing fracture risk, but 
also are most likely to remain at high fracture risk even after potent therapy, limiting 
attempts to treat to a specific desired target of BMD or fracture risk level [11, 12].   
Interestingly pre-index treatment with calcitonin or teriparatide before the adherent 
bisphosphonate period, and co-treatment with calcitonin and bisphosphonates, were 
both associated with increased fracture risk during months 13-36. This may be 
explainable by a greater likelihood for providers to treat higher risk patients with 
teriparatide, or to attempt combination therapy in those at higher risk.   However in 
univariate analysis, concomitant raloxifene did not influence risk of fractures or 
composite outcomes in bisphosphonate adherent subjects. Co-medication with 
raloxifene and bisphosphonates may occur due to the common practice of 
prescribing raloxifene for potential extra-skeletal benefits.  In short term clinical 
trials, raloxifene and alendronate in combination have been shown to increase BMD 
greater than either agent alone [27], although a fracture risk benefit from this 
combination therapy has not been demonstrated. 
According to the findings of Hochberg et al, both absolute BMD and the magnitude of 
change on treatment had additive effect on the risk of fractures in bisphosphonate 
treated subjects in clinical trials[16]. A significant decline in BMD was observed in 
16% of our subcohort having pre- and post-treatment DXA, which was considerably 
higher than in clinical trials[16, 17]. However the fracture rates were comparable 
between our study and clinical trials of oral bisphosphonates.  In fact, in our study, 
change in BMD did not predict the occurrence of clinical fractures, whether BMD 
change was evaluated as a continuous variable or as categories of change. The 
incidence of clinical fracture was similar whether there was an increase or decrease in 
BMD. This would suggest that measurements of BMD change in the context of clinical 
practice may be a poor surrogate for clinical fracture risk prediction. 
Sambrook showed that fractures could be predicted from relatively simple 
algorithms that performed as well as more complex ones.[28] Since older patients, 
non-black patients, and those with hyperparathyroidism or concomitant estrogen 
use tended to remain at higher risk of fracture despite being adherent to 
bisphosphonate treatment, these are the patients who may need to be considered 
early for alternative treatments or monitored more closely to decide whether they 
need alternative treatments.  Exactly what those criteria would be beyond BMD or 
new fractures are uncertain, as algorithms such as FRAX are not responsive 
enough to therapy to reliably detect a change in risk with therapy [12].   
In summary, despite adherence, a substantial proportion of patients in clinical practices 
treated with oral bisphosphonates remain at risk for fractures and a third of patients had 
one of the suboptimal clinical outcomes.  Although clinical trials have indicated a 
decrease in fracture risk even with declines in BMD during bisphosphonate therapy, the 
benefit achieved by such patients is not likely to be optimal. Further studies are required 
to identify which patients require alternate therapies to maximize their fracture reduction 
benefit, and how best to identify appropriate and achievable targets for goal-directed 
osteoporosis therapy.   
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Figure 1: Cohort Inclusions (n=7435) 
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Table 1: Demographics, adherence and pre-index bone-related measures, and 
comorbidities of the cohort. Values are provided as mean (SD) or N (%) 
  All (n=7435) 
Complete-outcomes  
Subcohort having 
pre and post-
adherent DXA 
(n=601) 
Demographics    
Age at index  68 (10) 66 (9) 
Race Black 493 (7%) 46 (8%) 
  Hispanic 23 (<1%) 5 (1%) 
  Missing 1228 (17%) 29 (5%) 
  White 5691 (77%) 521 (87%) 
Adherence Measures    
Proportion of days covered  0.96 (0.04) 0.96 (0.04) 
Length of Bisphosphonate Adherent 
Period (days)  1019 (272) 1053 (289) 
Length of Bisphosphonate Adherent 
Period (years) 2-2.224 1855 (25%) 104 (17%) 
  2.25-2.49 1336 (18%) 103 (17%) 
  2.5-2.74 1017 (14%) 91 (15%) 
  2.75-2.99 984 (13%) 95 (16%) 
  3+ 2243 (30%) 208 (35%) 
Pre-index Bone Measures    
Fracture pre-index  680 (9%) 62 (10%) 
Minimum T-score  within 2 years pre-index  ≤-2.5 350 (27%) 152 (25%) 
 >-2.5 953 (73%) 446 (75%) 
 Missing  6132 3a 
Pre-index Osteoporosis Medications    
Any osteoporosis drug  2249 (30%) 211 (35%) 
    Calcitonin  63 (1%) 6 (1%) 
    Teriparatide  33 (<1%) 4 (1%) 
    Any bisphosphonates  2215 (30%) 206 (34%) 
        Risedronate  692 (9%) 50 (8%) 
        Ibandronate  222 (3%) 23 (4%) 
        Alendronate  1441 (19%) 150 (25%) 
Comorbidities   
Mean Modified Charlson Comorbidity Index (SD) b 1.26 (1.78) 1.23 (1.86) 
AIDS 6 (<1%) 1 (<1%) 
Any Malignancy 1089 (15%) 100 (17%) 
Chronic pulmonary diseases 1599 (22%) 125 (21%) 
Inflammatory and other chronic joint conditions 2733 (37%) 233 (39%) 
Neurologic conditions 1805 (24%) 133 (22%) 
Cardiovascular conditions (other than cerebrovascular) 4272 (57%) 348 (58%) 
Diabetes 1035 (14%) 67 (11%) 
Hyperparathyroidism 67 (1%) 6 (1%) 
Vitamin D deficiency 401 (5%) 40 (7%) 
Renal disease 369 (5%) 24 (4%) 
Gastrointestinal disorders  1895 (25%) 159 (26%) 
a Three subjects in the complete outcomes cohort were missing pre-index T-scores, but BMD 
value (without listing T-score) was available from the existing reports. 
b The Charlson Comorbidity Index is a scale generated from ICD9 codes, and higher index 
values indicate greater comorbidities.  
 
 
Table 2: Medications used during the adherent period     
 All (n=7435) 
Complete-outcomes  
subcohort having pre and 
post-adherent DXA 
(n=601) 
Bisphosphonates a N (%) N (%) 
Risedronate 2011 (27%) 131 (22%) b 
Ibandronate sodium 774 (10%) 72 (12%) 
Alendronate 5254 (71%) 454 (76%) b 
Other Medications   
Calcitonin-salmon 66 (1%) 7 (1%) 
Estrogens 718 (10%) 41 (7%) c 
Tamoxifen 53 (1%) 6 (1%) 
Aromatase inhibitor 222 (3%) 25 (4%) 
Raloxifene 295 (4%) 28 (5%) 
Thiazide diuretics 1273 (17%) 95 (16%) 
Glucocorticoids 2602 (35%) 207 (34%) 
Proton pump inhibitors 1662 (22%) 119 (20%) 
SSRIs/SNRIs 1723 (23%) 143 (24%) 
Anticonvulsants 1138 (15%) 97 (16%) 
Statins 3283 (44%) 261 (43%) 
Antidiabetics 191 (3%) 19 (3%) 
Coumadin/anticoagulants 399 (5%) 27 (4%) 
Cyclosporin cytotoxic agents 107 (1%) 7 (1%) 
a Some subjects changed oral bisphosphonate during the adherent period. 
b p<0.01 
c p<0.05 
 
  
Table 3: Outcomes: Fracture, low T-score ≤ -2.5, change in BMD (from corresponding pre- to 
post-index periods), and composite outcomes 
Full cohort (n=7435) N (%) 
Fracture (7-36 months post-index) 499 (7%) 
Low T-score (minimum T-score ≤ -2.5) BMD from 13-36 
months post-index (n=1301) 264 (20%). 
  
Complete-outcomes  subcohort  
having pre and post-adherent DXA (n=601)  
Fracture (7-36 months post-index) 38 (6%) 
Low T-score (minimum T-score ≤ -2.5) from 13-36 months 
post-index 131 (22%) 
BMD change*  
Femur neck (n=236 patients)  
Mean (SD) of overall % change 0.71 (5.85) 
Increase ≥ 5% 51 (22%) 
Remained unchanged (within ± 5%)  148 (63%) 
Decrease ≥ 5% 37 (16%) 
Total hip (n=553)  
Mean (SD) of overall % change 1.28 (5.37) 
Increase ≥ 5% 112 (20%) 
Remained unchanged (within ± 5%) 393 (71%) 
Decrease ≥ 5% 48 (9%) 
Spine (n=506)  
Mean (SD) of overall % change 3.29 (7.58) 
Increase ≥ 5% 185 (37%) 
Remained unchanged (within ± 5%) 283 (56%) 
Decrease ≥ 5% 38 (8%) 
Worst BMD change at any site (n=601)  
Increase ≥ 5% 69 (11%) 
Remained unchanged (within ± 5%) 434 (72%) 
Decrease ≥ 5% 98 (16%) 
Mean of minimum % change at any site, mean (SD) -0.62 (5.55) 
  
Composite outcome (one or more of the following: fracture, 
minimum T-score ≤ -2.5, or BMD decrease ≥ 5%) 207 (35%) 
*Due to rounding, percent of patients in categories at a BMD site may not add up to exactly 
100%. Not every patient had data available for all 3 sites, so the numbers with DXA at each site 
varied. 
 
 
 
 
 
Table 4:  Prediction of 7-36 month post-index fracture by each individual predictor for entire cohort of 7435 women with 499 fracture 
outcomes: univariate estimates of association 
  Fracture No Fracture OR (95% CI) p-value 
   N (%) N (%)   
Total n= 7435  499 (6.7%) 6936 (93.3%)    
Age at index 
 
72.77 (10.98) 67.31 (10.29) 1.27 (1.22, 1.33) <0.0001 * 
Black race Yes 35 (7%) 458 (93%) 1.07 (0.75, 1.52) 0.7217 
 
 
No 464 (7%) 6478 (93%)   
 Fracture pre-index Yes 130 (19%) 550 (81%) 4.09 (3.29, 5.09) <0.0001 * 
 No 369 (5%) 6386 (95%)    
Minimum pre-index T-score of femoral neck, 
hip, spine ≤ -2.5  Yes 29 (8%) 321 (92%) 1.22 (0.83, 1.81) 0.3162  
 No 48 (5%) 905 (95%) 0.72 (0.53, 0.98) 0.0340 * 
 missing 422 (7%) 5710 (93%)    
Co-morbidities       
Modified Charlson Comorbidity Index, mean 
(SD)  (OR is given per 1 unit increase in 
index) a  
2.36 (2.35) 1.18 (1.70) 1.29 (1.24, 1.34) <0.0001 * 
AIDS Yes 2 (33%) 4 (67%) 6.97 (1.27, 38.17) 0.0251 * 
 No 497 (7%) 6932 (93%) 
   Any Malignancy Yes 103 (9%) 986 (91%) 1.57 (1.25, 1.97) 0.0001 * 
 
No 396 (6%) 5950 (94%) 
   Chronic pulmonary diseases Yes 163 (10%) 1436 (90%) 1.86 (1.53, 2.26) <0.0001 * 
 
No 336 (6%) 5500 (94%) 
   Inflammatory and other chronic joint 
conditions Yes 289 (11%) 2444 (89%) 2.53 (2.10, 3.04) <0.0001 * 
 
No 210 (4%) 4492 (96%) 
   Neurologic conditions Yes 229 (13%) 1576 (87%) 2.89 (2.40, 3.47) <0.0001 * 
 
No 270 (5%) 5360 (95%) 
   Cardiovascular conditions (other than 
cerebrovascular) Yes 383 (9%) 3889 (91%) 2.59 (2.09, 3.20) <0.0001 * 
 
No 116 (4%) 3047 (96%) 
   Diabetes Yes 119 (11%) 916 (89%) 2.06 (1.66, 2.56) <0.0001 * 
 
No 380 (6%) 6020 (94%) 
   Hyperparathyroidism Yes 5 (7%) 62 (93%) 1.12 (0.45, 2.80) 0.8051
 
 
No 494 (7%) 6874 (93%) 
   Vitamin D deficiency Yes 31 (8%) 370 (92%) 1.18 (0.81, 1.72) 0.4021
 
 
No 468 (7%) 6566 (93%) 
   Renal disease Yes 69 (19%) 300 (81%) 3.55 (2.68, 4.69) <0.0001 * 
 
No 430 (6%) 6636 (94%) 
   Gastrointestinal disorders Yes 160 (10%) 1387 (90%) 1.89 (1.55, 2.30) <0.0001 * 
 
No 339 (6%) 5549 (94%) 
   Pre-index treatments    
Risedronate pre-index Yes 51 (7%) 641 (93%) 1.12 (0.83, 1.51) 0.4675 
 
 
No 448 (7%) 6295 (93%) 
   Ibandronate sodium pre-index Yes 17 (8%) 205 (92%) 1.16 (0.70, 1.92) 0.5676
 
 
No 482 (7%) 6731 (93%) 
   Alendronate pre-index Yes 90 (6%) 1351 (94%) 0.91 (0.72, 1.15) 0.4314
 
 
No 409 (7%) 5585 (93%) 
   Any bisphosphonate treatment pre-index Yes 149 (7%) 2066 (93%) 1.00 (0.82, 1.22) 0.9725
 
 
No 350 (7%) 4870 (93%) 
   Calcitonin pre-index Yes 12 (19%) 51 (81%) 3.33 (1.76, 6.28) 0.0002 * 
 
No 487 (7%) 6885 (93%) 
   Teriparatide pre-index Yes 7 (21%) 26 (79%) 3.78 (1.63, 8.76) 0.0019 * 
 
No 492 (7%) 6910 (93%) 
   Any osteoporosis treatment pre-index Yes 152 (7%) 2097 (93%) 1.01 (0.83, 1.23) 0.9148
 
 
No 347 (7%) 4839 (93%) 
   Drugs during adherent period.    
Bisphosphonate type       
Risedronate during adherent period Yes 135 (7%) 1876 (93%) 1.00 (0.82, 1.23) 1.0000 
 
 
No 364 (7%) 5060 (93%) 
   Ibandronate sodium during adherent period Yes 51 (7%) 723 (93%) 0.98 (0.73, 1.32) 0.8866
 
 
No 448 (7%) 6213 (93%) 
   Alendronate during adherent period Yes 368 (7%) 4886 (93%) 1.18 (0.96, 1.45) 0.1179
 
 
No 131 (6%) 2050 (94%) 
   Additional concomitant medications during 
bisphosphonate adherent period       
Calcitonin during adherent period Yes 10 (15%) 56 (85%) 2.51 (1.28, 4.96) 0.0078 * 
 
No 489 (7%) 6880 (93%) 
   Glucocorticoids during adherent period Yes 178 (7%) 2424 (93%) 1.03 (0.85, 1.25) 0.7443
 No 321 (7%) 4511 (93%)    
Tamoxifen during adherent period Yes 7 (13%) 46 (87%) 2.13 (0.96, 4.75) 0.0638 
 
 
No 492 (7%) 6890 (93%) 
   Aromatase inhibitor during adherent period Yes 18 (8%) 204 (92%) 1.24 (0.76, 2.02) 0.3990
 
 
No 481 (7%) 6732 (93%) 
   Raloxifene during adherent period Yes 22 (7%) 273 (93%) 1.13 (0.72, 1.76) 0.6014
 
 
No 477 (7%) 6663 (93%) 
   Estrogens during adherent period Yes 52 (7%) 666 (93%) 1.10 (0.81, 1.48) 0.5506
 
 
No 447 (7%) 6269 (93%) 
   a The Charlson Comorbidity Index is a scale generated from ICD9 codes, and higher index values indicate greater comorbidities.  
* Marks significant p values. 
 
 
  
Table 5: Multivariable prediction of outcomes: Fractures in entire cohort and composite outcome in the complete-outcomes subcohort 
Outcome Predictor OR (95% CI) p-value 
Entire cohort (n= 7435)    
Fractures (1 or more)   Age at index 1.03 (1.02, 1.04) <0.0001 
 Charlson Comorbidity Index a 1.14 (1.09, 1.20) <0.0001 
 Inflammatory and other chronic joint conditions 1.64 (1.34, 2.00) <0.0001 
 Neurologic conditions 1.55 (1.25, 1.91) 0.0001 
 
Cardiovascular conditions (other than 
cerebrovascular) 1.33 (1.04, 1.68) 0.0206 
 Alendronate pre-index 0.69 (0.54, 0.89) 0.0037 
 Calcitonin pre-index 2.10 (1.07, 4.12) 0.0318 
 Fracture pre-index 2.59 (2.05, 3.28) <0.0001 
Complete-outcomes  subcohort 
having pre and post-adherent DXA 
(n=601)    
Composite outcome Age at index 1.05 (1.03, 1.08) <0.0001 
(Fractures, T-score ≤-2.5, BMD 
decrease ≥5%) Black race 0.37 (0.17, 0.79) 0.0105 
 Hyperparathyroidism 7.01 (1.18, 41.7) 0.0322 
 Estrogens during adherent period 2.41 (1.23, 4.71) 0.0100 
a The Charlson Comorbidity Index is a scale generated from ICD9 codes, and higher index values indicate greater comorbidities.  
 
Supplemental Table 1: ICD-9 codes used in the study 
Osteoporosis and fracture codes 
Osteopenia and Osteoporosis 2317, 3846, 733.0-733.03, 733.09, 733.9, 733.90 
Fracture codes used for outcome 
events 
733.1-733.16, 733.19, 805-808, 812-813, 818-821, 
823, 827-828 
Exclusion criteria 
Hypercalcemia 275.42 
Pagets Disease of Bone 731.0 
Osteogenesis Imperfecta 756.51 
Charlson comorbidity score components 
Any Malignancy 140-172, 174-195, 200-205  
Chronic Pulmonary Disease 490-496, 500-505, 506.4 
Diabetes (and Complications) 250 
Hemiplegia or Paraplegia 342, 344.1 
Mild Liver Disease 571.2, 571.4-571.6 
Myocardial Infarction 410 
Peptic Ulcer Disease 531-534 
Renal Disease 582-583, 585-586, 588 
Rheumatologic Disease 710, 714, 725 
Additional comorbidities included 
Celiac Disease 579 
Chronic Inflammatory Bowel 555-556 
Chronic Inflammatory Joint 714-715 
Depression 311 
Gastrointestinal & Urination  788 
Glucocorticoid therapy 255.41 
Hyperparathyroidism 252 
Hypertension 401-405 
Neurologic Conditions 326, 330-336, 340-345, 355-359 
Renal Impairment 585-585.6, 585.9 
Vitamin D Deficiency 268, 268.9 
 Supplemental Table 2; Secondary analysis using 2 or more fractures as an outcome. 
Outcome Predictor OR (95% CI) p-value 
Entire cohort (n= 7435)    
Fractures (2 or more) Age at index 1.04 (1.03, 1.06) <0.0001 
  Charlson Comorbidity Index 1.16 (1.09, 1.24) <.0001 
  Black race 0.43 (0.20, 0.93) 0.0316 
  Inflammatory and other chronic joint 
conditions 
2.49 (1.78, 3.49) <0.0001 
  Neurologic conditions 1.80 (1.29, 2.53) 0.0006 
  Alendronate pre-index 0.59 (0.39, 0.91) 0.0164 
Complete-outcomes  subcohort 
having pre and post-adherent DXA 
(n=601) 
   
Composite outcome 
(2 or more fractures,  
T-score≤-2.5, or 
BMD decrease ≥ 5%) 
Age at index 1.05 (1.03, 1.08) <0.0001 
Black race 0.40 (0.18, 0.90) 0.0272 
Diabetes 0.51 (0.27, 0.96) 0.0374 
Hyperparathyroidism 9.58 (1.62, 56.74) 0.0128 
  Risedronate during adherent period 1.74 (1.15, 2.66) 0.0096 
  Estrogens during adherent period 2.20 (1.12, 4.33) 0.0227 
 
